Find a Doctor

Gino K. In

Usc Care Medical Group Inc
Hematology, Oncology, Internal Medicine
Male
Practicing approx. 11 years

Bio


Gino In is a Hematologist and an Oncologist in Los Angeles, California. He has been an author on 20 peer reviewed articles and participated in 25 clinical trials in the past 15 years. He is licensed to treat patients in CA.

Contact

1441 Eastlake Ave
Los Angeles, CA 90089, US

Latest Advances


This doctor has not participated in any recent research.

Clinical Trials


Clinical Trial
  • Status: Not yet recruiting
  • Phase: Phase 1
  • Intervention Type: Other, Biological, Drug
  • Participants: 16
  • Start Date: June 1, 2020
Short-Term Fasting Prior to Standard Checkpoint Blockade Using PD-1/PD-L1 Inhibition: A Pilot Safety and Feasibility Study
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 59
  • Start Date: May 17, 2019
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Biological, Procedure
  • Participants: 500
  • Start Date: December 6, 2018
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Radiation, Biological
  • Participants: 500
  • Start Date: October 1, 2018
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Procedure, Biological
  • Participants: 56
  • Start Date: October 20, 2016
A Phase II and Pilot Trial of PD-1 Blockade With MK-3475 (Pembrolizumab) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Biological, Other, Drug
  • Participants: 75
  • Start Date: October 25, 2013
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)

All Publications
View All


Publication
Conference
  • Sponsor: Society for ImmunoTherapy of Cancer (SITC)
  • Event Name: Society for ImmunoTherapy of Cancer Annual Scientific Meeting 2020
  • Published —
BASAL CELL CARCINOMA DEMONSTRATES A T-CELL EXCLUSION IMMUNE PHENOTYPE IN CONTRAST TO OTHER ANTI-PD-1 THERAPY RESPONSIVE CUTANEOUS MALIGNANCIES
Publication
Study
  • Journal: Cancer treatment and research communications
  • Published —
Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center.

Contact

1441 Eastlake Ave
Los Angeles, CA 90089, US

Affiliations

  • Usc Kenneth Norris Jr Cancer Hospital
  • Keck Hospital Of Usc
  • Lac+usc Medical Center
  • Huntington Memorial Hospital

Credentials

  • Licenses
    Internal Medicine in CA
  • Board Certifications
    Hematology/oncology
    Internal Medicine

Insurance

Contact them to find out if they accept your insurance plan.